The use of buprenorphine in the treatment of chronic pain in the pain clinic

被引:0
|
作者
Jakubow, Piotr [1 ,2 ,3 ]
Kosel, Dariusz [2 ,3 ]
Kosciuczyk, Urszula [2 ,3 ]
Jarocka, Malgorzata [3 ]
Kopczynska, Antonina [3 ]
Domalewska, Aneta [3 ,4 ]
Ejsmont, Anna [3 ,5 ]
机构
[1] Uniwersytet Med Bialymstoku, Zaklad Farmakol Klin, Sklodowskiej 24a, PL-15215 Bialystok, Poland
[2] Uniwersytet Med Bialymstoku, Klin Anestezjol & Intensywnej Terapii, Bialystok, Poland
[3] Poradnia Leczenia Bolu NZOZ Vitamed, Bialystok, Poland
[4] Hosp Stacjonarne Dom Opatrznosci Bozej Bialymstok, Bialystok, Poland
[5] Uniwersytet Med Bialymstoku, Klin Psychiat, Bialystok, Poland
来源
MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE | 2016年 / 8卷 / 02期
关键词
opioids; buprenorphine; noncancer pain;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: The increased use of opioids in the treatment of chronic non-cancer pain has been observed in recent years. Buprenorphine is an opioid analgesic with an established position in pain therapy. Due to the unique pharmacological profile it is attractive to use in the outpatient clinic. The big advantage of the drug is the lack of tolerance induced by opioids and, theoretically, a high safety profile. The aim of the study is to analyse the use and safety profile of buprenorphine in patients with chronic nonmalignant pain at the Outpatient Pain Treatment Clinic. Material and methods: The records of patients treated at the Outpatient Pain Treatment Clinic were subjected to a retrospective analysis, as it was reported to the National Health Fund. Results: Buprenorphine was used in 9% of patients and it represented more than 50% in the group of opioid drugs. The largest group of patients consisted of those with the back pain in the lumbosacral segment. The most demanded choice was transdermal buprenorphine. There were no serious complications or critical side effects. For 3% of patients aged 65 years and more it was necessary to reduce the dose to improve the cognitive function. Due to the skin side effects it was also necessary to rotate the transdermal formulation. Conclusions: Buprenorphine, which is preferred as the treatment of choice in chronic non-malignant pain syndromes, is also effective and safe. The dose and form of the drug should be adjusted to the state and condition of the patient.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 50 条
  • [31] Increasing buprenorphine access for patients with chronic pain: a quality improvement initiative
    Wesolowicz, Danielle M.
    Spelman, Juliette F.
    Edmond, Sara N.
    Schwartz, Amy R.
    Kravetz, Jeffrey D.
    Edens, Ellen L.
    Becker, William C.
    PAIN MEDICINE, 2024, 25 (03) : 226 - 230
  • [32] Sublingual Buprenorphine as an Analgesic in Chronic Pain: A Systematic Review
    Cote, Joyce
    Montgomery, Lori
    PAIN MEDICINE, 2014, 15 (07) : 1171 - 1178
  • [33] Transdermal buprenorphine for moderate chronic noncancer pain syndromes
    Pergolizzi, Joseph V., Jr.
    Coluzzi, Flaminia
    Taylor, Robert, Jr.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (05) : 359 - 369
  • [34] Treating Chronic Pain with Buprenorphine-The Practical Guide
    Case, Amy A.
    Kullgren, Justin
    Anwar, Sidra
    Pedraza, Sandra
    Davis, Mellar P.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (12)
  • [35] Evaluation of Chronic, Noncancer Pain Management Initiative in a Multidisciplinary Pain Clinic
    Panicker, Latha
    Prasun, Marilyn A.
    Stockmann, Cherrill
    Simon, Jolene
    PAIN MANAGEMENT NURSING, 2022, 23 (02) : 122 - 127
  • [36] Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study
    Muriel Villoria, Clemente
    Perez-Castejon Garrote, Juan Manuel
    Sanchez Magro, Isabel
    Neira Alvarez, Marta
    MEDICINA CLINICA, 2007, 128 (06): : 204 - 210
  • [37] Use of sublingual buprenorphine for pain relief in office hysteroscopy
    Lin, YH
    Hwang, JL
    Huang, LW
    Chen, HJ
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2005, 12 (04) : 347 - 350
  • [38] Transdermal Buprenorphine Use for Pain Management in Palliative Care
    Hirsch, Jessica M.
    Kale, Sachin S.
    Palettas, Marilly
    Kullgren, Justin
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2022, 35 (04) : 254 - 259
  • [39] Microinduction to Buprenorphine from Methadone for Chronic Pain: Outpatient Protocol with Case Examples
    Silva, Marcelina Jasmine
    Coffee, Zhanette
    Goza, Jessica
    Rumrill, Kelly
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2022, 36 (01) : 40 - 48
  • [40] The chronic pain patient and functional assessment: use of the 6-Minute Walk Test in a multidisciplinary pain clinic
    Peppin, John F.
    Marcum, Steve
    Kirsh, Kenneth L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (03) : 361 - 365